| Primary |
| Pulmonary Arterial Hypertension |
23.1% |
| Prophylaxis |
19.2% |
| Hypertension |
15.4% |
| Atrial Fibrillation |
7.7% |
| Atrial Flutter |
7.7% |
| Metastatic Renal Cell Carcinoma |
7.7% |
| Arteriosclerosis Coronary Artery |
3.8% |
| Bladder Disorder |
3.8% |
| Deep Vein Thrombosis |
3.8% |
| Depression |
3.8% |
| Pollakiuria |
3.8% |
|
| Dizziness |
11.1% |
| Gastroenteritis Viral |
11.1% |
| Gastrointestinal Haemorrhage |
11.1% |
| Haematemesis |
11.1% |
| Hepatic Fibrosis |
11.1% |
| Hypocalcaemia |
11.1% |
| Liver Injury |
11.1% |
| Melaena |
11.1% |
| Skin Disorder |
11.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
17.7% |
| Product Used For Unknown Indication |
15.0% |
| Atrial Fibrillation |
9.2% |
| Chronic Obstructive Pulmonary Disease |
7.8% |
| Hypertension |
7.5% |
| Suicide Attempt |
5.2% |
| Thrombosis Prophylaxis |
4.6% |
| Cardiac Failure |
3.6% |
| Atrial Flutter |
3.1% |
| Hypokalaemia |
3.0% |
| Anticoagulant Therapy |
2.9% |
| Coronary Artery Disease |
2.6% |
| Prophylaxis |
2.6% |
| Accidental Exposure |
2.6% |
| Supraventricular Tachycardia |
2.5% |
| Epilepsy |
2.3% |
| Pulmonary Arterial Hypertension |
2.3% |
| Major Depression |
2.1% |
| Sedation |
1.7% |
| Dermatitis |
1.6% |
|
| Toxic Epidermal Necrolysis |
17.2% |
| International Normalised Ratio Increased |
16.0% |
| Prothrombin Time Prolonged |
11.0% |
| Suicide Attempt |
6.1% |
| Transaminases Increased |
6.1% |
| White Blood Cell Count Increased |
4.3% |
| Gastrointestinal Haemorrhage |
3.7% |
| Thrombocytopenia |
3.7% |
| Bradycardia |
3.1% |
| Leukocytoclastic Vasculitis |
3.1% |
| Prothrombin Time Shortened |
3.1% |
| Stevens-johnson Syndrome |
3.1% |
| Anaemia |
2.5% |
| Coagulation Time Abnormal |
2.5% |
| Drug Interaction |
2.5% |
| Hypoaesthesia |
2.5% |
| Nausea |
2.5% |
| Premature Baby |
2.5% |
| Renal Failure |
2.5% |
| Renal Failure Acute |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.3% |
| Drug Use For Unknown Indication |
15.9% |
| Hypertension |
12.1% |
| Atrial Fibrillation |
10.9% |
| Rheumatoid Arthritis |
6.1% |
| Cardiac Failure |
3.4% |
| Pulmonary Arterial Hypertension |
3.2% |
| Osteoporosis |
2.7% |
| Diabetes Mellitus |
2.4% |
| Prophylaxis |
2.2% |
| Thrombosis Prophylaxis |
2.1% |
| Pain |
1.8% |
| Multiple Myeloma |
1.8% |
| Depression |
1.8% |
| Pulmonary Hypertension |
1.7% |
| Coronary Artery Disease |
1.6% |
| Anticoagulant Therapy |
1.3% |
| Arrhythmia |
1.3% |
| Breast Cancer |
1.3% |
| Type 2 Diabetes Mellitus |
1.2% |
|
| Vomiting |
8.1% |
| Thrombocytopenia |
7.2% |
| Pulmonary Embolism |
6.5% |
| Renal Failure |
6.5% |
| Pyrexia |
5.8% |
| Prothrombin Time Prolonged |
5.6% |
| Death |
5.4% |
| Renal Failure Acute |
5.4% |
| Syncope |
5.4% |
| Weight Decreased |
5.1% |
| Pneumonia |
4.9% |
| Tachycardia |
4.9% |
| Weight Increased |
4.2% |
| Transaminases Increased |
4.0% |
| Atrial Fibrillation |
3.8% |
| Dyspnoea |
3.6% |
| Rhabdomyolysis |
3.6% |
| Nausea |
3.4% |
| Ventricular Fibrillation |
3.4% |
| Cardiac Failure |
3.2% |
|
| Interacting |
| Drug Use For Unknown Indication |
22.9% |
| Hypertension |
13.6% |
| Product Used For Unknown Indication |
12.5% |
| Atrial Fibrillation |
12.2% |
| Type 2 Diabetes Mellitus |
5.0% |
| Helicobacter Gastritis |
4.3% |
| Pain |
3.9% |
| Insomnia |
3.6% |
| Atrial Flutter |
3.2% |
| Hairy Cell Leukaemia |
2.2% |
| Cardiac Disorder |
1.8% |
| Goitre |
1.8% |
| Mitral Valve Stenosis |
1.8% |
| Oedema Peripheral |
1.8% |
| Pulmonary Embolism |
1.8% |
| Syncope |
1.8% |
| Deep Vein Thrombosis |
1.4% |
| Diabetes Mellitus |
1.4% |
| Mitral Valve Replacement |
1.4% |
| Myocardial Ischaemia |
1.4% |
|
| International Normalised Ratio Increased |
18.5% |
| Drug Interaction |
17.4% |
| Prothrombin Time Prolonged |
13.0% |
| Prothrombin Time Shortened |
6.5% |
| Melaena |
5.4% |
| Prothrombin Time Abnormal |
5.4% |
| Drug Effect Increased |
3.3% |
| Hemiparesis |
3.3% |
| International Normalised Ratio Decreased |
3.3% |
| Renal Failure Acute |
3.3% |
| International Normalised Ratio |
2.2% |
| Muscle Haemorrhage |
2.2% |
| Prothrombin Level Decreased |
2.2% |
| Shock Haemorrhagic |
2.2% |
| Somnolence |
2.2% |
| Subarachnoid Haemorrhage |
2.2% |
| Thrombin Time Abnormal |
2.2% |
| Transaminases Increased |
2.2% |
| Weight Decreased |
2.2% |
| Blood Glucose Increased |
1.1% |
|
